The neuromuscular network for Canada

funder-logos_nmd4c

Lawrence Korngut

lawrence-korngut

Adult Neuromuscular Neurologist; Director, Calgary Neuromuscular Program

Associate Professor, Department of Clinical Neurosciences, Hotchkiss Brain Institute, University of Calgary

Email Lawrence

Read more about Lawrence

Biography

Dr Lawrence Korngut is a neurologist, clinical neurophysiologist and Director of the Calgary Neuromuscular Program and the Calgary ALS and Motor Neuron Disease Clinic. His research includes phase II and III clinical trials of new therapies for neuromuscular conditions. He is the National Principal Investigator of the Canadian Neuromuscular Disease Registry that now includes 31 participating clinics and over the past ten years has recruited over 4400 patients.

Dr Korngut is the former Chair of the Canadian Neuromuscular Diseases Network (CAN-NMD), which was funded by the Canadian Institutes of Health Research and Muscular Dystrophy Canada in 2014 and consists of a nationwide collaboration of researchers, clinicians, and allied health professionals aiming to improve the lives those affected by neuromuscular conditions through improving clinical care, research capacity and education. He is the former Chair of the Medical and Scientific Advisory Committee and served on the Board of Directors of Muscular Dystrophy Canada.

Dr Korngut completed his undergraduate degree in Life Sciences at Queen’s University (Kingston, Canada), medical school and neurology residency at Western University (London, Canada), neuromuscular clinical and research fellowship and Masters of Science in Clinical Epidemiology at the University of Calgary, Alberta, Canada. He serves as the Director of Innovation and Commercialization at the Hotchkiss Brain Institute.

Within NMD4C Dr Korngut will bring in his experience of Canadian networking in CAN-NMD and participates in the network’s work in trial capacity building.

Recent publications

Pugliese, M, Tingley, K, Chow, A, Pallone, N, Smith, M, Rahman, A et al.. Outcomes in pediatric studies of medium-chain acyl-coA dehydrogenase (MCAD) deficiency and phenylketonuria (PKU): a review. Orphanet J Rare Dis. 2020.15 (1)12 PMID:31937333

E Elahi, GMM, Kalra, S, Zinman, L, Genge, A, Korngut, L, Yang, YH et al.. Texture classification of MR images of the brain in ALS using M-CoHOG: A multi-center study. Comput Med Imaging Graph. 2020.79 101659 PMID:31786374

Srivastava, O, Hanstock, C, Chenji, S, Mah, D, Eurich, D, Ta, D et al.. Cerebral degeneration in amyotrophic lateral sclerosis: A prospective multicenter magnetic resonance spectroscopy study. Neurol Clin Pract. 2019.9 (5)400-407 PMID:31750025

Wood, L, Bassez, G, Bleyenheuft, C, Campbell, C, Cossette, L, Jimenez-Moreno, AC et al.. Correction to: Eight years after an international workshop on myotonic dystrophy patient registries: case study of a global collaboration for a rare disease. Orphanet J Rare Dis. 2019.14 (1)199 PMID:31416449

Shefner, JM, Cudkowicz, ME, Hardiman, O, Cockcroft, BM, Lee, JH, Malik, FI et al.. A phase III trial of tirasemtiv as a potential treatment for amyotrophic lateral sclerosis. Amyotroph Lateral Scler Frontotemporal Degener. 2019.0 (0)1-11 PMID:31081694

Almomen, M, Martens, K, Quadir, A, Pontifex, CS, Hanson, A, Korngut, L et al.. High diagnostic yield and novel variants in very late-onset spasticity. J. Neurogenet. 2019.33 (1)27-32 PMID:30747022

Lee, JY, Crooks, RE, Pham, T, Korngut, L, Patten, S, Jetté, N et al.. "If it helps someone, then I want to do it": Perspectives of persons living with dementia on research registry participation. Dementia (London). 2019. 1471301219827709 PMID:30722693

Hodgkinson, VL, Lounsberry, J, Mirian, A, Genge, A, Benstead, T, Briemberg, H et al.. Provincial Differences in the Diagnosis and Care of Amyotrophic Lateral Sclerosis. Can J Neurol Sci. 2018.45 (6)652-659 PMID:30430962

Wood, L, Bassez, G, Bleyenheuft, C, Campbell, C, Cossette, L, Jimenez-Moreno, AC et al.. Eight years after an international workshop on myotonic dystrophy patient registries: case study of a global collaboration for a rare disease. Orphanet J Rare Dis. 2018.13 (1)155 PMID:30185236

Campbell, C, Selby, K, McMillan, H, Vajsar, J, Korngut, L, Brais, B et al.. Response to the Canadian Agency for Drugs and Technologies in Health and Institut national d'excellence en santé et en services sociaux decision regarding nusinersen for Spinal Muscular Atrophy. Can J Neurol Sci. 2018.45 (5)516-517 PMID:30039778

See more on PubMed

Read next...

Cynthia-Gagnon

Cynthia Gagnon

reshma-amin

Reshma Amin

perry-esler

Perry Esler

maryam-oskoui

Maryam Oskoui

bernard-brais

Bernard Brais